 12 AM / Updated 3 minutes ago BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs Reuters Staff 
Jan 3 (Reuters) - United Therapeutics Corp: 
* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS 
* UNITED THERAPEUTICS SAYS GRANTED EXCLUSIVE LICENSE TO CORSAIR‘S INTELLECTUAL PROPERTY FOR DEVELOPMENT OF TREPROSTINIL PRODRUG FORMULATIONS 
* UNITED THERAPEUTICS CORP - MADE MINORITY EQUITY INVESTMENT IN CORSAIR THAT INCLUDES AN OPTION TO ACQUIRE REMAINING OUTSTANDING SHARES OF CORSAIR 
* UNITED THERAPEUTICS SAYS UNDER TERMS OF LICENSE AGREEMENT, CORSAIR RECEIVED UPFRONT CONSIDERATION 
* UNITED THERAPEUTICS- CORSAIR IS ENTITLED TO ROYALTY PAYMENTS ON COMMERCIALIZATION OF TREPROSTINIL PRODRUG PRODUCTS BY CO COVERED BY CORSAIR‘S PATENTS Source text for Eikon: Further company coverage: